Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Volume: 379, Issue: 11, Pages: 1007 - 1016
Published: Sep 13, 2018
Abstract
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation and...
Paper Details
Title
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Published Date
Sep 13, 2018
Volume
379
Issue
11
Pages
1007 - 1016
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History